TScan Therapeutics Reports Q1 2025 Financial Results

Tscan Therapeutics, Inc. ( (TCRX) ) has released its Q1 earnings. Here is a breakdown of the information Tscan Therapeutics, Inc. presented to its investors.

TScan Therapeutics, Inc. is a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies aimed at treating cancer patients, with a focus on both hematologic malignancies and solid tumors.

In its first-quarter 2025 earnings report, TScan Therapeutics highlighted its ongoing progress in clinical trials and strategic appointments. The company is advancing its PLEXI-T solid tumor and ALLOHA heme Phase 1 clinical trials, with updates expected by the end of the year, and is on track to file an IND application for TSC-102-A0301 with the FDA in the latter half of 2025.

Key financial metrics for the first quarter of 2025 include a revenue increase to $2.2 million from $0.6 million in the same period last year, primarily due to research activities with Amgen. Research and development expenses rose to $29.8 million, driven by increased laboratory and personnel costs, while general and administrative expenses increased to $8.6 million. The company reported a net loss of $34.1 million, up from $30.1 million in the first quarter of 2024.

Strategically, TScan has appointed Stephen Camiolo as Senior Vice President of Market Access to strengthen its commercial leadership. The company is also preparing for a significant presence at upcoming industry events, including a presentation at the American Society of Gene and Cell Therapy Annual Meeting.

Looking ahead, TScan remains focused on advancing its clinical programs and anticipates significant milestones, including the initiation of a registrational trial for TSC-101 and the dosing of the first patient with multiplex TCR-T therapy. The company is confident that its cash reserves will support operations into the first quarter of 2027, positioning it well for future growth and development in the TCR-T therapy space.